Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New blood test kit checked for accuracy and stability

NCT ID NCT06905392

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at a blood test kit called NTproBNP2, used on the AQT90 FLEX analyzer, which measures a substance linked to heart stress. Researchers wanted to see if the test works the same with different types of blood samples and how long those samples stay reliable. A total of 154 adults took part. The goal was to make sure the test gives consistent results for diagnosing heart conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

154 people

The number who actually took part.

Started

May 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient population with expected NT-proBNP concentrations within the measuring range of NTproBNP2 Test Kit.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must be able to understand given information and demonstrate willingness and ability to voluntarily give a signed, valid written informed consent to participate in the study. * Subjects must be 18 years of age or older. * Subjects with expected NT-proBNP concentrations within the measuring range of NTproBNP2 Test Kit. Exclusion Criteria: * Subjects known to be pregnant or breast-feeding. * Subjects previously enrolled in the study. * Subject, who has withdrawn consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diagnostic tests are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Hennepin Healthcare (Research Institute/ Minneapolis Medical Research Foundation)

    Minneapolis, Minnesota, 55404, United States

  • Hospital Clinico Universitario de Santiago Compostela

    Santiago de Compostela, Spain

  • Hospital Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Servicio Andaluz de Salud (SAS) - Hospital San Juan de la Cruz

    Ùbeda, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.